文献速递临床试验与 GCP流行病学与生物统计

基层医疗中膝骨关节炎风险评估与管理项目(RAMP):一项为期一年的实用性随机对照试验

Risk Assessment and Management Program (RAMP) on knee osteoarthritis in primary care-a one-year pragmatic randomized controlled trial.
PubMed 文献 · Trials · 2026-02-03

本研究为52周、双臂、平行、开放标签随机对照试验,评估RAMP-Knee OA慢性照护模式与常规照护在膝骨关节炎成人中的临床效果,计划纳入RAMP组114例和常规照护组114例。主要结局为52周时WOMAC疼痛评分,次要结局涵盖身体功能、下肢肌肉量、身体活动、自我管理效能、焦虑抑郁、失眠、孤独感及健康相关生活质量,采用协方差分析调整基线值。

要点

  • RAMP-Knee OA为整合风险评估、照护方案、自我管理支持和定期健康评估的慢性照护模式。
  • 试验在基层医疗环境中比较RAMP-Knee OA与常规照护,随访52周。
  • 主要结局为52周时WOMAC疼痛评分(5点Likert量表)。

核心结论

  • 研究结果将用于填补在香港实施包含综合风险评估、照护方案、自我管理支持和定期健康评估的慢性照护模式时证据与实践之间的差距。

研究设计与样本

  • 52周、双臂、平行、开放标签随机对照试验,RAMP-Knee OA组N=114,常规照护组N=114。
  • 测量在基线、16周、32周和52周进行。
  • 主要分析采用协方差分析调整基线值,次要分析调整潜在混杂因素并探索治疗与潜在调节因素的交互效应。

主要发现

  • 原文未报告结果数据。

关键数值与推荐

  • 主要结局为52周时WOMAC疼痛评分(5点Likert量表)。
  • 次要结局包括WOMAC功能子量表、30秒坐立试验、生物电阻抗分析测下肢肌肉量、中文国际身体活动问卷简表、疼痛自我效能问卷、GAD-7、PHQ-9、7项失眠严重指数、6项De Jong Gierveld孤独量表及EuroQuol-5D问卷。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Knee osteoarthritis (OA) is the most common chronic arthritis and is a leading cause of pain and disability. Chronic care model (CCM) has been proved successful in Hong Kong primary care setting. This study aims to assess the clinical effectiveness of a CCM, named Assessment and Management Program on Knee Osteoarthritis (RAMP-Knee OA), compared to usual care in adults with knee OA. METHODS: The study is a 52-week, two-arm, parallel, open-label randomized clinical trial, evaluating the clinical efficacy of RAMP-Knee OA (N = 114) versus usual care (N = 114) on self-reported knee pain and other secondary outcomes. Measurement instruments will be tested at baseline, 16, 32, and 52 weeks. The primary outcome will be the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC; 5-point Likert) pain at 52 weeks. Secondary outcomes include a set of biopsychosocial parameters: Physical function will be measured subjectively by WOMAC function subscale and objectively by the 30-second chair and stand performance test. Lower limb muscle mass will be measured by bioimpedance analysis. Physical activity level will be measured by the Chinese International Physical Activity Questionnaire (Short form). Self-management efficacy will be measured by Pain-Self Efficacy questionnaire. Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) will be used to measure anxiety and depression, respectively. Insomnia will be measured by the 7-item Insomnia Severity Index (ISI), and loneliness will be measured by the 6-item De Jong Gierveld Loneliness Scale. EuroQuol-5D questionnaire will be used to measure health-related quality of life. Both primary and secondary outcomes at different points will be conducted using analysis of covariance, adjusting for baseline values. Secondary analyses include adjustments for potential confounders and exploration of interaction effects of treatment and the potential moderators. DISCUSSION: The findings will address the evidence-to-practice gap for the implementation of a CCM that incorporates a comprehensive risk assessment, care protocol, self-management support, and scheduled health assessments in Hong Kong. TRIAL REGISTRATION: ClinicalTrials.gov, 1 NCT06283147. Registered on 22 February 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sit RW, Yip BH, Choi SY, et al. Risk Assessment and Management Program (RAMP) on knee osteoarthritis in primary care-a one-year pragmatic randomized controlled trial. Trials. 2026. PMID: 41629997. doi:10.1186/s13063-026-09469-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。